Top

Thrombosis Journal

Published in:

Open Access 01-12-2005 | Original clinical investigation

Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels

Authors: Catharina Borna, Eduardo Lazarowski, Catharina van Heusden, Hans Öhlin, David Erlinge

Published in: Thrombosis Journal | Issue 1/2005

Abstract

Background

To be fully activated platelets are dependent on two positive feedback loops; the formation of thromboxane A₂ by cyclooxygenase in the platelets and the release of ADP. We wanted to evaluate the effect of aspirin on platelet function in patients with acute coronary syndromes and we hypothesized that increased levels of ADP in patients with acute coronary syndromes could contribute to aspirin resistance.

Methods

Platelet activity in 135 patients admitted for chest pain was assessed with PFA-100. An epinephrine-collagen cartridge (EPI-COLL) was used for the detection of aspirin resistance together with an ADP-collagen cartridge (ADP-COLL). ADP was measured with hplc from antecubital vein samples. Three subgroups were compared: chest pain with no sign of cardiac disease (NCD), NonST-elevation myocardial infarction (NSTEMI) and STEMI.

Results

Platelet activation was increased for the STEMI group compared NCD. Aspirin resistance defined as <193 sec in EPI-COLL was 9.7 % in NCD, and increased to 26.0 % (n.s.) in NSTEMI and 83.3 % (p < 0.001) in STEMI. Chronic aspirin treatment significantly reduced platelet aggregation in NCD and NSTEMI, but it had no effect in STEMI. Plasma levels of ADP were markedly increased in STEMI (905 ± 721 nmol/l, p < 0.01), but not in NSTEMI (317 ± 245), compared to NCD (334 ± 271, mean ± SD). ADP levels correlated with increased platelet activity measured with ADP-COLL (r = -0.30, p < 0.05). Aspirin resistant patients (EPI-COLL < 193 sec) had higher ADP levels compared to aspirin responders (734 ± 807 vs. 282 ± 187 nmol/l, mean ± SD, p < 0.05).

Conclusion

Platelets are activated and aspirin resistance is more frequent in STEMI, probably due to a general activation of platelets. ADP levels are increased in STEMI and correlates with platelet activation. Increased levels of ADP could be one reason for increased platelet activity and aspirin resistance.

Available only for authorised users

Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324: 71-86. 10.1136/bmj.324.7336.S71CrossRef

CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348: 1329-39. 10.1016/S0140-6736(96)09457-3CrossRef

The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001, 345: 494-502. 10.1056/NEJMoa010746CrossRef

Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288: 2411-20. 10.1001/jama.288.19.2411CrossRefPubMed

Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A: Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002, 107: 45-49. 10.1016/S0049-3848(02)00210-4CrossRefPubMed

Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001, 88: 230-235. 10.1016/S0002-9149(01)01631-9CrossRefPubMed

Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993, 71: 397-403. 10.1016/0049-3848(93)90164-JCrossRefPubMed

Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol E: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41: 961-965. 10.1016/S0735-1097(02)03014-0CrossRefPubMed

Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105: 1650-5. 10.1161/01.CIR.0000013777.21160.07CrossRefPubMed

10.

Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA: Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Hemost 1995, 21(Suppl 2):106-12.PubMed

11.

Lazarowski ER, Boucher RC, Harden TK: Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. J Biol Chem 2000, 275: 31061-31068. 10.1074/jbc.M003255200CrossRefPubMed

12.

Levitt B, Head RJ, Westfall DP: High-pressure liquid chromatographic fluorometric detection of adenosine and adenine nucleotides: application to endogenous content and electrically induced release of adenyl purines in guinea pig vas deferens. Anal Biochem 1984, 137: 93-100. 10.1016/0003-2697(84)90352-XCrossRefPubMed

13.

Kristensen SD, Bath PM, Martin JF: Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina. Cardiovasc Res 1990, 24: 19-23.CrossRefPubMed

14.

Milner PC, Martin JF: Shortened bleeding time in acute myocardial infarction and its relation to platelet mass. Br Med J (Clin Res Ed) 1985, 290: 1767-70.CrossRef

15.

Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K: Towards a definition of aspirin resistance: a typological approach. Platelets 2002, 1: 37-40. 10.1080/09537100120104890CrossRef

16.

Altman R, Luciardi HL, Muntaner J, Herrera RN: The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J 2004, 2: 1. 10.1186/1477-9560-2-1PubMedCentralCrossRefPubMed

17.

Hillarp A, Lethagen S, Mattiasson I: Aspirin resistance is not a common biochemical phenotype explained by unblocked cyclooxygenase-1 activity. J Thromb Haemost 2003, 1: 196-197. 10.1046/j.1538-7836.2003.00012.xCrossRefPubMed

18.

Kawasaki T, Ozeki Y, Igawa T, Kambayashi J: Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000, 31: 591-5.CrossRefPubMed

19.

Rasmanis G, Vesterqvist O, Green K, Edhag O, Henriksson P: Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction. Lancet 1988, 2(8605):245-7. 10.1016/S0140-6736(88)92537-8CrossRefPubMed

20.

Heper G, Bayraktaroglu M: The importance of von Willebrand factor level and heart rate changes in acute coronary syndromes: a comparison with chronic ischemic conditions. Angiology 2003, 54: 287-99.CrossRefPubMed

21.

Buerke M, Pittroff W, Meyer J, Darius H: Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 1995, 130(3 Pt 1):465-72. 10.1016/0002-8703(95)90353-4CrossRefPubMed

22.

Malhotra S, Sharma YP, Grover A, Majumdar S, Hanif SM, Bhargava VK, Bhatnagar A, Pandhi P: Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease. Intern Med J 2003, 33: 350-4. 10.1046/j.1445-5994.2003.00360.xCrossRefPubMed

23.

Gordon JL: Extracellular ATP: effects, sources and fate. Biochem J 1986, 233: 309-19.PubMedCentralCrossRefPubMed

24.

Vassort G: Adenosine 5'-Triphosphate: a P2-purinergic agonist in the myocardium. Physiological Reviews 2001, 767-806.

25.

Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, Sanchez E, Broekman MJ, Marcus AJ: Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998, 97: 350-355.CrossRefPubMed

26.

Storey RF, Newby LJ, Heptinstall S: Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001, 12: 443-7. 10.1080/09537100120085450CrossRefPubMed

27.

Wang L, Östberg O, Wihlborg A-K, Brogren H, Jern S, Erlinge D: Quantification of ADP and ATP Receptor Expression in Human Platelets. J Thromb & Haem 2003, 1: 330-336. 10.1046/j.1538-7836.2003.00070.xCrossRef

28.

González-Alonso J, Olsen DB, Saltin B: Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery. Role of circulating ATP. Circ Res 2002, 91: 1046-1055. 10.1161/01.RES.0000044939.73286.E2CrossRefPubMed

Title: Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels
Authors: Catharina Borna
Eduardo Lazarowski
Catharina van Heusden
Hans Öhlin
David Erlinge
Publication date: 01-12-2005
Publisher: BioMed Central
Published in: Thrombosis Journal / Issue 1/2005
Electronic ISSN: 1477-9560
DOI: https://doi.org/10.1186/1477-9560-3-10

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2005

Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis

Increased PAI-1 plasma levels and risk of death from dengue: no association with the 4G/5G promoter polymorphism

Catheter-related septic thrombophlebitis of the great central veins successfully treated with low-dose streptokinase thrombolysis and antimicrobials

Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar

Intermittent pneumatic compression for prevention of pulmonary thromboembolism after gynecologic surgery

Comparison of incidence/risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: A community-based cohort study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials